Summary
According to APO Research, the global Nucleic Acids for Molecular Diagnosis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Nucleic Acids for Molecular Diagnosis market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Nucleic Acids for Molecular Diagnosis market include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Nucleic Acids for Molecular Diagnosis, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nucleic Acids for Molecular Diagnosis, also provides the value of main regions and countries. Of the upcoming market potential for Nucleic Acids for Molecular Diagnosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nucleic Acids for Molecular Diagnosis revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Nucleic Acids for Molecular Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Nucleic Acids for Molecular Diagnosis company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Nucleic Acids for Molecular Diagnosis Segment by Company
Agilent Technologies, Inc.
Aji Bio-Pharma
Bio-synthesis Inc.
Danaher Corporation
Eurofins Scientific SE
Integrated DNA Technologies
Kaneka Eurogentec S.A.
L.G.C Biosearch Technologies
Merck KGaA
metabion
QIAGEN
Thermo Fisher Scientific Inc.
Hongene
Synthgene
Nucleic Acids for Molecular Diagnosis Segment by Type
DNA Series
RNA Series
Nucleic Acids for Molecular Diagnosis Segment by Application
Early Cancer Screening
Genetic Diseases
Blood Screening
Genome Sequencing
Infectious Diseases
Other
Nucleic Acids for Molecular Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Nucleic Acids for Molecular Diagnosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Nucleic Acids for Molecular Diagnosis key companies, revenue, market share, and recent developments.
3. To split the Nucleic Acids for Molecular Diagnosis breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Nucleic Acids for Molecular Diagnosis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nucleic Acids for Molecular Diagnosis significant trends, drivers, influence factors in global and regions.
6. To analyze Nucleic Acids for Molecular Diagnosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Acids for Molecular Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
1: Introduces the report scope of the report, global total market size.
2: Analysis key trends, drivers, challenges, and opportunities within the global Nucleic Acids for Molecular Diagnosis industry.
3: Detailed analysis of Nucleic Acids for Molecular Diagnosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
6: Sales value of Nucleic Acids for Molecular Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
7: Sales value of Nucleic Acids for Molecular Diagnosis in country level. It provides sigmate data by type, and by application for each country/region.
8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Nucleic Acids for Molecular Diagnosis Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Nucleic Acids for Molecular Diagnosis Market Dynamics
- 2.1 Nucleic Acids for Molecular Diagnosis Industry Trends
- 2.2 Nucleic Acids for Molecular Diagnosis Industry Drivers
- 2.3 Nucleic Acids for Molecular Diagnosis Industry Opportunities and Challenges
- 2.4 Nucleic Acids for Molecular Diagnosis Industry Restraints
- 3 Nucleic Acids for Molecular Diagnosis Market by Company
- 3.1 Global Nucleic Acids for Molecular Diagnosis Company Revenue Ranking in 2024
- 3.2 Global Nucleic Acids for Molecular Diagnosis Revenue by Company (2020-2025)
- 3.3 Global Nucleic Acids for Molecular Diagnosis Company Ranking (2023-2025)
- 3.4 Global Nucleic Acids for Molecular Diagnosis Company Manufacturing Base and Headquarters
- 3.5 Global Nucleic Acids for Molecular Diagnosis Company Product Type and Application
- 3.6 Global Nucleic Acids for Molecular Diagnosis Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Nucleic Acids for Molecular Diagnosis Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Nucleic Acids for Molecular Diagnosis Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Nucleic Acids for Molecular Diagnosis Market by Type
- 4.1 Nucleic Acids for Molecular Diagnosis Type Introduction
- 4.1.1 DNA Series
- 4.1.2 RNA Series
- 4.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type
- 4.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Type (2020-2031)
- 4.2.3 Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Type (2020-2031)
- 5 Nucleic Acids for Molecular Diagnosis Market by Application
- 5.1 Nucleic Acids for Molecular Diagnosis Application Introduction
- 5.1.1 Early Cancer Screening
- 5.1.2 Genetic Diseases
- 5.1.3 Blood Screening
- 5.1.4 Genome Sequencing
- 5.1.5 Infectious Diseases
- 5.1.6 Other
- 5.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application
- 5.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Application (2020-2031)
- 5.2.3 Global Nucleic Acids for Molecular Diagnosis Sales Value Share by Application (2020-2031)
- 6 Nucleic Acids for Molecular Diagnosis Regional Value Analysis
- 6.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2020-2031)
- 6.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region: 2020-2025
- 6.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Nucleic Acids for Molecular Diagnosis Sales Value (2020-2031)
- 6.3.2 North America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Nucleic Acids for Molecular Diagnosis Sales Value (2020-2031)
- 6.4.2 Europe Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Nucleic Acids for Molecular Diagnosis Sales Value (2020-2031)
- 6.6.2 South America Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Sales Value Share by Country, 2024 VS 2031
- 7 Nucleic Acids for Molecular Diagnosis Country-level Value Analysis
- 7.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2020-2031)
- 7.2.1 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2020-2025)
- 7.2.2 Global Nucleic Acids for Molecular Diagnosis Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.7.2 France Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.14.2 China Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.17.2 India Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Nucleic Acids for Molecular Diagnosis Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Agilent Technologies, Inc.
- 8.1.1 Agilent Technologies, Inc. Comapny Information
- 8.1.2 Agilent Technologies, Inc. Business Overview
- 8.1.3 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.1.5 Agilent Technologies, Inc. Recent Developments
- 8.2 Aji Bio-Pharma
- 8.2.1 Aji Bio-Pharma Comapny Information
- 8.2.2 Aji Bio-Pharma Business Overview
- 8.2.3 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.2.5 Aji Bio-Pharma Recent Developments
- 8.3 Bio-synthesis Inc.
- 8.3.1 Bio-synthesis Inc. Comapny Information
- 8.3.2 Bio-synthesis Inc. Business Overview
- 8.3.3 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.3.5 Bio-synthesis Inc. Recent Developments
- 8.4 Danaher Corporation
- 8.4.1 Danaher Corporation Comapny Information
- 8.4.2 Danaher Corporation Business Overview
- 8.4.3 Danaher Corporation Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.4.5 Danaher Corporation Recent Developments
- 8.5 Eurofins Scientific SE
- 8.5.1 Eurofins Scientific SE Comapny Information
- 8.5.2 Eurofins Scientific SE Business Overview
- 8.5.3 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.5.5 Eurofins Scientific SE Recent Developments
- 8.6 Integrated DNA Technologies
- 8.6.1 Integrated DNA Technologies Comapny Information
- 8.6.2 Integrated DNA Technologies Business Overview
- 8.6.3 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.6.5 Integrated DNA Technologies Recent Developments
- 8.7 Kaneka Eurogentec S.A.
- 8.7.1 Kaneka Eurogentec S.A. Comapny Information
- 8.7.2 Kaneka Eurogentec S.A. Business Overview
- 8.7.3 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.7.5 Kaneka Eurogentec S.A. Recent Developments
- 8.8 L.G.C Biosearch Technologies
- 8.8.1 L.G.C Biosearch Technologies Comapny Information
- 8.8.2 L.G.C Biosearch Technologies Business Overview
- 8.8.3 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.8.5 L.G.C Biosearch Technologies Recent Developments
- 8.9 Merck KGaA
- 8.9.1 Merck KGaA Comapny Information
- 8.9.2 Merck KGaA Business Overview
- 8.9.3 Merck KGaA Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.9.5 Merck KGaA Recent Developments
- 8.10 metabion
- 8.10.1 metabion Comapny Information
- 8.10.2 metabion Business Overview
- 8.10.3 metabion Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.10.5 metabion Recent Developments
- 8.11 QIAGEN
- 8.11.1 QIAGEN Comapny Information
- 8.11.2 QIAGEN Business Overview
- 8.11.3 QIAGEN Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.11.5 QIAGEN Recent Developments
- 8.12 Thermo Fisher Scientific Inc.
- 8.12.1 Thermo Fisher Scientific Inc. Comapny Information
- 8.12.2 Thermo Fisher Scientific Inc. Business Overview
- 8.12.3 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.12.5 Thermo Fisher Scientific Inc. Recent Developments
- 8.13 Hongene
- 8.13.1 Hongene Comapny Information
- 8.13.2 Hongene Business Overview
- 8.13.3 Hongene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.13.5 Hongene Recent Developments
- 8.14 Synthgene
- 8.14.1 Synthgene Comapny Information
- 8.14.2 Synthgene Business Overview
- 8.14.3 Synthgene Nucleic Acids for Molecular Diagnosis Revenue and Gross Margin (2020-2025)
- 8.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
- 8.14.5 Synthgene Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook